PDSB stock news · PDS Biotechnology Corp
Get alerts for PDSB
Follow PDS Biotechnology Corp (PDSB) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PDSBPDS Biotechnology Corp has four directors leaving and three new ones joining the board.
NeutralPDS Biotechnology added 3 directors after 4 resigned. The new members bring relevant experience, but no dispute or business change was reported, leaving the outlook unchanged.
Here are 12 health care stocks that changed a lot during Friday's trading.
NeutralPDS Biotechnology shares rose 21% during Friday's session. The report gives no company news behind the move, so it does not change what we know about the business.
12 health care companies saw big price changes during Tuesday's trading.
NeutralPDS Biotechnology shares fell about 19% during Tuesday's session. The article gives no company news explaining the drop, so it does not change the company's outlook.
PDS Biotechnology Corp: Other Events (PDSB)
NeutralPDS Biotechnology plans an online expert discussion of PDS0301 trial outcomes, focused on metastatic colorectal cancer. The filing gives no results, so it does not change the company's prospects.
12 health care stocks are changing a lot during Monday's trading.
NeutralPDS Biotechnology shares rose 69.68% during Monday’s session, but the story reports no company news explaining the move. The price change alone does not alter its business outlook.
12 health care companies saw big changes during Monday's trading.
NeutralPDS Biotechnology's shares rose 70% on Monday. The story gives no company news to show that its business prospects changed.
PDS Biotechnology Corp shared new information in a report on September 21, 2026.
NeutralPDS Biotechnology filed an updated corporate presentation deck that includes no new financial or operational information, so the news is neutral for PDSB.
On Tuesday, 12 health care stocks saw big price changes during the day.
Good for PDSBPDS Biotechnology moved up 40.95% to $0.31, showing a large positive market reaction in the session.
PDS Biotechnology Corp details leadership transitions, including the exit and election of directors, along with the appointment and compensation arrangements for specific officers (PDSB).
NeutralPDS Biotechnology Corp has filed a Form 8-K detailing significant changes in its leadership, including the departure and appointment of certain directors and officers. Such changes can lead to shifts in company strategy and investor sentiment, making it crucial for stakeholders to monitor the situation closely.
PDS Biotechnology Shares Plummet as Company Shifts Focus to Metastatic Colorectal Cancer Initiative.
NeutralPDS Biotechnology's stock has plummeted by approximately 67% following the announcement of a strategic refocus on its PDS0301 program for metastatic colorectal cancer. This decision reflects a shift in resources towards a program deemed to have more potential for long-term shareholder value, but the immediate market reaction has been overwhelmingly negative, pushing the stock to a new 52-week low.